Early Phase 1 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a specific hormone condition called Cushing disease, confirmed through blood or urine tests showing overproduction of a hormone called ACTH.
- People who have not had previous surgery on the pituitary gland (a small gland at the base of the brain).
- People who are already planned to have pituitary surgery to find and/or remove a small growth (adenoma) on the pituitary gland.
- People who have no medical reasons preventing them from having a PET/CT scan (a type of imaging scan).
- People who have had, or are scheduled to have, an MRI scan of the pituitary gland within 3 months of the study's PET/CT scan.
- People aged 18 or older.
- People who are able to understand and sign a consent form agreeing to take part.
Who may not be able to join:
- People who are pregnant, as determined by a pregnancy test following the trial site's standard guidelines.
- People of childbearing potential who are not willing to use effective contraception during the study.
- People who need urgent surgery that would be delayed by taking part in the trial.
- People who have an active bacterial, viral, or fungal infection that requires treatment with medication taken throughout the body (such as oral or intravenous antibiotics or antifungals).
- People with serious other health conditions — such as kidney failure, liver failure, or inflammatory or autoimmune diseases — that the trial doctor believes could put the patient at risk or affect the study's goals.
- People who have a known diagnosis of an autoimmune disorder.
- People who have taken part in another clinical trial and received an experimental treatment within the past 28 days.
- People who are currently breastfeeding, unless they are willing to pump and discard breast milk from the time of the study injection until at least 24 hours after it.
- People who are known to have an allergy or sensitivity to any ingredients used in the study's imaging agent (called FET).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Derek Johnson, MD, Mayo Clinic
Phone: 507-284-2950
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity of FET PET results in comparison to histopathology; Specificity of FET PET results in comparison to histopathology; Accuracy of FET PET results in comparison to histopathology
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.